Loading organizations...
Key people at NDA Group AB.
NDA Group AB provides specialized regulatory consulting to pharmaceutical and biotechnology companies, guiding them through complex drug development and approval processes. The firm crafts comprehensive regulatory strategies, facilitates interactions with global health authorities like the FDA and EMA, and develops multi-jurisdictional dossiers, accelerating market entry.
Founded in 1997 by Birgitta Bergstrand and Lars-Helge Strömquist, NDA Group AB originated from the insight that specialized regulatory expertise was vital for navigating the evolving pharmaceutical development landscape. They recognized the critical need for strategic guidance, bridging the gap between innovative life science companies and global health authority requirements.
NDA Group AB serves a broad clientele across pharmaceutical and biotechnology sectors. The company’s vision centers on enabling faster patient access to innovative therapies by ensuring robust and efficient global regulatory pathways. Leveraging deep regulatory knowledge, they empower clients to successfully navigate approvals and bring vital medicines to market.
Key people at NDA Group AB.
NDA Group AB is an independent regulatory and drug‑development consulting firm that helps biotech and pharmaceutical companies navigate regulatory affairs, health‑technology assessment (HTA), pharmacovigilance and quality‑assurance work so that medicines reach patients faster and with compliant dossiers. [1][3]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Life‑Sciences Landscape
Quick Take & Future Outlook
If you’d like, I can: provide a concise competitor map (other regulatory consultancies and their relative strengths), compile recent public case examples of NDA’s role in specific approvals, or draft outreach language to engage NDA for an advisory project.